Sun Pharmaceutical Industries has scheduled a board meeting on October 12, 2026, to consider a non-convertible debenture (NCD) issue of up to ₹15,000 crore through private placement.

Board meeting details

The following key details have been disclosed regarding the proposed fundraise:

The board will deliberate on the proposal to raise funds via listed and rated NCDs. This debt instrument is commonly used by corporates to access capital markets through a select group of investors rather than a public offering.

Regulatory disclosure

The company intimated the National Stock Exchange and BSE under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms the NCDs will be rated and redeemable, issued in one or more tranches for an aggregate amount not exceeding ₹15,000 crore.

Sun Pharmaceutical Industries Limited announced the establishment of the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai. The initiative is supported by a $2.5 million endowment from Sun Pharma to fund academic leadership in perpetuity.

Mark G. Lebwohl, M.D., has been installed as the inaugural professor. The ceremony took place on October 6, 2026, at Hatch Auditorium at The Mount Sinai Hospital in New York. The professorship is based within the Kimberly and Eric J. Waldman Department of Dermatology.

Strategic Alignment with Core Business

Sun Pharma identifies itself as the second-largest pharmaceutical dermatology company in the U.S. by prescription volume. This endowment aligns with its broader commitment to advancing patient care through scientific innovation and education. The company’s Global Innovative Medicines portfolio, which includes dermatology products, accounts for about 22% of total sales.

Leadership and Institutional Impact

Dr. Lebwohl serves as Dean for Clinical Therapeutics at the Icahn School of Medicine and Professor and Chairman Emeritus of the Department of Dermatology. He is internationally recognized for his contributions to psoriasis research and for shaping standards of care in inflammatory skin diseases.

Ahmad Naim, M.D., Senior Vice President and Chief Medical Officer, North America, stated that the professorship reflects a long-term commitment to fostering academic leadership needed to pursue new ideas and strengthen care for generations to come.

Emma Guttman, M.D., Ph.D., Waldman Professor and System Chair of the Department of Dermatology, noted that the partnership reflects a shared belief in investing in scientific excellence. Eric J. Nestler, M.D., Ph.D., Dean of the Icahn School of Medicine, described the professorship as a fitting recognition of Dr. Lebwohl's impact on the field.

What the Numbers Show

The $2.5 million endowment is structured to support research, education, and mentorship indefinitely. By anchoring this funding within a department where it already holds significant market presence, Sun Pharma reinforces its position in the U.S. dermatology sector. The move highlights a strategic focus on long-term academic influence rather than short-term commercial returns.